Medvi Peptides: What the GLP-1 Program Actually Offers

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial review by PlexusDx. There is no commercial relationship with Medvi, no affiliate arrangement, and no compensation behind any statement below.

People searching "Medvi peptides" often expect a research-peptide catalog. That expectation is worth correcting up front: Medvi is a GLP-1 weight-management program, not a broad peptide vendor. This overview lays out exactly which peptides Medvi works with, how a prescription is filled, and where a genetic map fits. Fair-balance framing, current as of April 2026.

Is Medvi a peptide provider?

Only in the GLP-1 sense. As of our July 2026 review, Medvi’s published menu is compounded semaglutide injection, compounded tirzepatide injection, and a once-daily dissolvable GLP-1 tablet, plus branded Wegovy and Zepbound through a separate membership. We found no broader therapeutic-peptide lineup and no retatrutide on the live site. Check Medvi’s official website for the current menu.

The GLP-1 compounds on Medvi’s menu

The peptides Medvi does handle all belong to the incretin family. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a GIP/GLP-1 dual agonist. Both are peptides in the pharmacological sense, but they are prescription medications routed through licensed pharmacies — not the unregulated "research peptides" some shoppers have in mind. The dissolvable tablet delivers a GLP-1 compound in a once-daily oral form.

How a Medvi peptide prescription is filled

A patient completes an intake covering weight, medical history, and medications. A licensed clinician reviews it and, where eligibility is met, issues a prescription. Compounded peptides route to a 503A compounding pharmacy; branded products route to a retail pharmacy. Ongoing telehealth follow-up supports dose titration and side-effect management. Provider type and pharmacy partner vary between programs.

What the peptide plans cost

On the compounded plans, the ongoing rate is $299/month for semaglutide and $399/month for tirzepatide. Medvi also sells prepaid multi-month plans, but the rates it publishes on an ongoing basis are $299/month for semaglutide and $399/month for tirzepatide. Compounded plans carry no membership fee; the dissolvable tablet’s price shows after intake.

Peptide science behind the GLP-1 class

These peptides work by engaging incretin receptors that regulate appetite and glucose. The evidence base includes STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints vary, and individual outcomes vary too.

The genetic map behind every peptide response

No telehealth peptide program reads the biology it prescribes into. FTO (fat-mass and obesity-associated), GLP1R (the receptor these peptides target), MC4R (central to satiety), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) map the terrain any GLP-1 peptide operates on. These pathway-level variants do not predict response to a specific compound, but they describe the system a clinician prescribes into. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — alongside the Precision Peptide Genetic Test, which analyzes 14 pathways, 49 peptides, 150+ genetic insights. That is the test before you invest approach.

Not affiliated: PlexusDx has no relationship with Medvi and no commercial tie to the companies named here.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols; this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare approaches: see the Weight Management Protocols, or take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Does Medvi sell research peptides?

No. As of our July 2026 review, Medvi is a GLP-1 weight-management program, not a research-peptide vendor. Its menu is compounded semaglutide, compounded tirzepatide, a dissolvable GLP-1 tablet, and branded Wegovy and Zepbound. We found no broader peptide catalog on its live site.

Which peptides are on Medvi’s menu?

The GLP-1 incretin peptides: semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GIP/GLP-1 dual agonist), plus a dissolvable GLP-1 tablet. All are prescription medications routed through licensed pharmacies after clinical review, not the unregulated peptides some shoppers picture.

Are Medvi’s peptides FDA-approved?

The compounded semaglutide and tirzepatide are prepared by licensed 503A pharmacies and are not FDA-approved brand products; the branded Wegovy and Zepbound routes are. The distinction between a compounded preparation and an approved brand is worth confirming directly on Medvi’s site before enrolling.

How does the genetic test relate to peptide therapy?

It does not predict how you will respond to any peptide. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape your baseline GLP-1 biology — upstream context that stays relevant regardless of which peptide or telehealth program you eventually use.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education